Pediatric research
Intravitreal Bevacizumab nanoparticles ameliorates retinal vasculopathy in an in vivo mouse model of retinopathy of prematurity.
Suganesh Raghunathan, Ben Amadi, Alfiya Raja, Olachi J Mezu-Ndubuisi
Published: 202510.1038/s41390-025-04508-w
Abstract
BACKGROUND: Nanoparticles enable sustained drug release. Infants with retinopathy of prematurity (ROP) treated with Bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody, develop systemic toxicity due to repeat dosing from a sho…
Preview only. Read the full abstract at the source